Patent

[8] Wang H, Bo Y. METHODS AND KITS FOR REDUCING THE RISK OF ALLOGRAFT REJECTION. Provisional Patent Application No. 63/550,246

[7] Wang H, Liu Y. METABOLIC TAGGING AND TARGETING OF RED BLOOD CELLS. U.S. Provisional Patent Application No. 63/402,413

[6] Liu Y, Mooney D, Wang H. COMPOSITIONS AND METHODS FOR LOCALIZED DELIVERY OF CYTOKINES FOR ADOPTIVE CELL THERAPY. U.S. Provisional Patent Application No. 63/330,562

[5] Wang H, Bhatta R, Han JS. MODIFIED EXOSOMES AND METHODS OF USE. U.S. Provisional Patent Application No. 63/333,001.

[4] Wang H, Khalil A, Mooney D, Jaenisch R. Methods for Labeling and Targeting Cells. U.S. Provisional Patent Application No. 62/967,387.

[3] Najibi A, Shah N, Wang H, Mooney D. Biomaterials-Based Antigen Free Vaccine and The Use Thereof. U.S. Provisional Patent Application No. 62/904,446.

[2] Mooney D, Wang H. Compositions and Methods for Labeling and Modulation of Cells In Vitro and In Vivo. US Patent App. 17/206,050.

[1] Cheng J, Wang H. Trigger-Activatable Metabolic Sugar Precursors for Cancer-Selective Labeling and Targeting. US Patent No. 11,014,953. WO2017062800A1, EP3371200A1, CN108699095A, JP2018535198A. (Start-up company: Iria Pharma)